Skip to main content
Premium Trial:

Request an Annual Quote

Interpace Biosciences: Fortunato Ron Rocca, Felice Schnoll-Sussman, James Early, Fred Knechtel, Jeff Salzman

Interpace Biosciences has appointed Fortunato Ron Rocca as a class II director. Rocca will serve on the firm's board as a non-employee director. Concurrently with the appointment, Felice Schnoll-Sussman has resigned from Interpace Bio's board. Rocca currently serves as president and CEO of Exagen.

Interpace Bio also said that CFO and Treasurer James Early is retiring from the firm. Early will be replaced by Fred Knechtel, who previously served as CFO at Genewiz. 

Interpace Bio has also appointed Jeff Salzman as VP of managed care and payor relations. Prior to Interpace Bio, Salzman held roles at Quest Diagnostics, Monogram Biosciences, Vermillion, and most recently at CareDx. 

The Scan

Tens of Millions Saved

The Associated Press writes that vaccines against COVID-19 saved an estimated 20 million lives in their first year.

Supersized Bacterium

NPR reports that researchers have found and characterized a bacterium that is visible to the naked eye.

Also Subvariants

Moderna says its bivalent SARS-CoV-2 vaccine leads to a strong immune response against Omicron subvariants, the Wall Street Journal reports.

Science Papers Present Gene-Edited Mouse Models of Liver Cancer, Hürthle Cell Carcinoma Analysis

In Science this week: a collection of mouse models of primary liver cancer, and more.